paroxysmal nocturnal hemoglobinuria (PNH) | Page 8 | Aplastic Anemia & MDS International Foundation Return to top.

paroxysmal nocturnal hemoglobinuria (PNH)

Secondary Myelodysplastic Syndrome and Leukemia in Acquired Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria

Lova Sun, Daria V Babushok
Primary Author: 
Sun, Lova
Journal Title: 
Original Publication Date: 
May 2020


Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry

Hubert Schrezenmeier, Alexander Röth, David J Araten, Yuzuru Kanakura, Loree Larratt, Jamile M Shammo, Amanda Wilson, Gilda Shayan, Jaroslaw P Maciejewski
Primary Author: 
Schrezenmeier, H
Journal Title: 
Annals of Hematology
Original Publication Date: 
May 2020

The International

Ilene Weitz, MD

Weitz, Ilene
Professor of Clinical Medicine
University of Southern California

Dr. Ilene C. Weitz is an Associate Professor of Clinical Medicine at the Keck School of Medicine at the University of Southern California (USC). Her practice sites include, LAC+USC Medical Center, Keck Hospital of USC and USC Norris Cancer Hospital. Dr. Weitz is board certified in Internal Medicine and Hematology.

Nikolai Podoltsev, MD, PhD

Podoltsev, Nikolai
Associate Director of the Hematology/Oncology Fellowship Program
Smilow Cancer Hospital at Yale

Dr. Podoltsev practice is focused on myeloid neoplasms including acute myelogenous leukemias (AML), myelodisplastic syndromes (MDS), myeloproliferative neoplasms (MPNs) like polycythemia vera (PV), essential thrombocythemia (ET), myelofibrosis (MF), chronic myelogenous leukemia (CML) among others. He is providing care for patients with

2020 National Virtual Patient & Family Conference

AAMDSIF hosted the 2020 National Patient & Family Conference ONLINE over three days, July 17 - 19, 2020. The Conference featured three days of educational workshops, panels and speakers for patients, families and caregivers with

Event Date: 
Thu, 07/16/2020 - 8:00pm (EDT) to Sat, 07/18/2020 - 8:00pm (EDT)

Study to Assess Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of RO7112689 in Healthy Volunteers and Participants With Paroxysmal Nocturnal Hemoglobinuria

This is a Phase I/II, first-in-human study consisting of four sequential parts and an open-label extension (OLE). The safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of RO7112689 will be evaluated in healthy volunteers (HV) during part 1. The safety, tolerability, PK and PD of multiple doses of RO7112689 will be evaluated in participants with

2020 Patient & Family Spring Virtual Conference


Due to the coronavirus (COVID-19) pandemic, AAMDSIF made the decision to move our conferences online in order to protect the health of our patients, families, caregivers and faculty.

We would like to acknowledge the support of our many generous patients, families and caregivers as well as our corporate partners including Celgene, Alexion, Novartis, Genentech, Jazz Pharmaceuticals, Apellis and Acceleron.

Event Date: 
Fri, 04/24/2020 - 8:00pm (EDT)
Conference Event Type: 
Share with